1/5
🚨 First-in-class RIPTAC™ in mAPMR
Thrilled to see this beautifully presented by @BGarmezy at #ESMO26.
JNJ-6143 is a first-in-class RIPTAC™ targeting AR × BRD4, designed to induce BRD4 loss of function and prostate cancer cell death.
21 views · 0 likes · 0 reposts · 4 replies
- Miguel Zugman, MD@mzugman
@OncoAlert @weoncologists
- Miguel Zugman, MD@mzugman
4/5 Safety was favorable, with mostly grade 1–2 TRAEs. At 50 mg QD, the most frequent TRAEs were nausea, headache, increased cholesterol and hypertriglyceridemia.
- Miguel Zugman, MD@mzugman
3/5 PSA responses were observed across high-risk molecular features, including AR amplification, AR-V7, AR LBD mutations, TP53, PTEN and RB1 alterations.
- Miguel Zugman, MD@mzugman
2/5 At 50 mg QD in heavily pretreated mCRPC: • 69% ORR (11/16) • 13% CR + 56% PR • 88% DCR • Median DOR: 11.0 months • 77% confirmed PSA50 • 48% confirmed PSA90
Source: Miguel Zugman, MD · x.com